Lessons From the Strategics
One of the more memorable moments from the Medtech MVP conference was Medtronic CEO Geoff Martha’s advice that medtech firms must think beyond individual devices and toward broader ecosystems. That comment is especially relevant to neuromodulation, where therapies have historically been developed around discrete implantable or wearable devices. In pain, movement disorders, epilepsy, sleep, migraine, and other neurological conditions, the next generation of systems is increasingly likely to depend on patient selection tools, device-generated data, digital workflow support, remote monitoring, and payer-aligned outcome tracking.
Medtech Execs Discuss M&A Activity in Minneapolis
There has been a wealth of acquisitions in the neurotechnology and related medtech industries in recent months. Two of the largest acquirers have been Boston Scientific, which has picked up Axonics, Nalu, and Valencia Technologies, and Medtronic, which acquired SPR Therapeutics for over $600 million last month. Executives from both major strategics offered their insights on the M&A outlook at the recent Medtech MVP conference in Minneapolis.